Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
7.67
+0.48 (6.68%)
Feb 11, 2026, 2:50 PM CST
Market Cap1.05B -1.7%
Revenue (ttm)370.00K
Net Income-37.78M
EPS-0.28
Shares Out137.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume59,107
Average Volume135,418
Open7.36
Previous Close7.19
Day's Range7.20 - 7.67
52-Week Range5.25 - 10.20
Beta-0.85
RSI58.68
Earnings DateMar 24, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements